Development and in vitro evaluation of a nanoemulsion for transcutaneous delivery

Drug Development and Industrial Pharmacy

Volumn 40, Issue 3, 2014, Pages 370-379

  Ledet, Grace ^a   Pamujula, Sarala ^a   Walker, Valencia ^a   Simon, Shana ^a   Graves, Richard ^a   Mandal, Tarun K ^a  

^a XAVIER UNIVERSITY OF LOUISIANA   (United States)

Author keywords

FITC BSA; Nanoemulsion; Nanotechnology; Skin; Squalane; Transcutaneous delivery; Vaccine delivery

Indexed keywords

BOVINE SERUM ALBUMIN; EXCIPIENT; FLUORESCEIN ISOTHIOCYANATE; POLYSORBATE 80; SORBITAN OLEATE; VACCINE;

ANIMAL TISSUE; ARTICLE; COMPARATIVE STUDY; CONJUGATE; CONTROLLED STUDY; CREAM; DIFFUSION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; HYPERBARISM; IN VITRO STUDY; MOUSE; NANOEMULSION; NONHUMAN; PARTICLE SIZE; PHASE SEPARATION; PROTEIN DEGRADATION; SKIN SURFACE; SOLUBILIZATION; STEADY STATE; VISCOSITY; WATER CONTENT; ZETA POTENTIAL;

ADMINISTRATION, CUTANEOUS; ANIMALS; CHEMISTRY, PHARMACEUTICAL; DRUG DELIVERY SYSTEMS; DRUG STABILITY; DRUG STORAGE; EMULSIONS; EXCIPIENTS; FLUORESCEIN-5-ISOTHIOCYANATE; MICE; MICE, INBRED BALB C; NANOPARTICLES; PARTICLE SIZE; PERMEABILITY; SERUM ALBUMIN, BOVINE; SKIN ABSORPTION; SURFACE-ACTIVE AGENTS; VACCINES; VISCOSITY;

EID: 84893924582     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2012.763137     Document Type: Article

References (40)

1. Kogan A, Garti N. Microemulsions as transdermal drug delivery vehicles. Adv Colloid Interface Sci 2006;123-126:369-85.
2. Glenn GM, Kenney RT. Mass vaccination: solutions in the skin. Curr Topics Microbio Immunol 2006;403:247-68.
3. Combadiere B, Mahe B. Particle-based vaccines for transcutaneous vaccination. Comp Immunol Microbiol Infect Dis 2008;31:293-315.
4. Baboota S, Shakeel F, Ahuja A, Ali J, Shafiq S. Design, development and evaluation of novel nanoemulsion formulations for transdermal potential of celecoxib. Acta Pharm 2007;57:315-32.
5. Cui Z, Sloat BR. Topical immunization onto mouse skin using a microemulsion incorporated with an anthrax protective antigen protein-encoding plasmid. Int J Pharm 2006;317:187-91.
6. Foldvari M, Babiuk S, Badea I. DNA delivery for vaccination and therapeutics through the skin. Curr Drug Deliv 2006;3:17-28.
7. Guglielmini G. Nanostructured novel carrier for topical application. Clin Dermatol 2008;26:341-6.
8. Hoeller S, Sperger A, Valenta C. Lecithin based nanoemulsions: a comparative study of the influence of non-ionic surfactants and the cationic phytosphingosine on physicochemical behaviour and skin permeation. Int J Pharm 2009;370:181-6.
9. Kotyla T, Kuo F, Moolchandani V, et al. Increased bioavailability of a transdermal application of a nano-sized emulsion preparation. Int J Pharm 2008;347:144-8.
10. Shakeel F, Baboota S, Ahuja A, et al. Nanoemulsions as vehicles for transdermal delivery of aceclofenac. AAPS Pharm Sci Tech 2007;8:191-9.
11. Tadros T, Izquierdo P, Esquena J, Solans C. Formation and stability of nano-emulsions. Adv Colloid Interface Sci 2004;108:303-18.
12. Tagliabue A, Rappuoli R. Vaccine adjuvants: the dream becomes real. Hum Vaccin 2008;4:347-9.
13. Fox CB. Squalene emulsions for parenteral vaccine and drug delivery. Molecules 2009;14:3286-312.
14. Shafiq-un-Nabi S, Shakeel F, Talegaonkar S, et al. Formulation development and optimization using nanoemulsion technique: a technical note. AAPS Pharm Sci Tech 2007;8:E12-17.
15. Anton N, Vandamme TF. Nano-emulsions and micro-emulsions: clarifications of the critical differences. Pharm Res 2011;28:978-85.
16. Wooster TJ, Golding M, Sanguansri P. Impact of oil type on nanoemulsion formation and Ostwald ripening stability. Langmuir 2008;24:12758-65.
17. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227:680-5.
18. Cardamone JM. Investigating the microstructure of keratin extracted from wool: peptide sequence (MALDI-TOF/TOF) and protein conformation (FTIR). J Mol Struct 2010;969:97-105.
19. Davies DJ, Ward RJ, Heylings JR. Multi-species assessment of electrical resistance as a skin integrity marker for in vitro percutaneous absorption studies. Toxicol In Vitro 2004;18:351-8.
20. Elshafeey AH, Kamel AO, Fathallah MM. Utility of nanosized microemulsion for transdermal delivery of tolterodine tartrate: ex-vivo permeation and in-vivo pharmacokinetic studies. Pharm Res 2009;26:2446-53.
21. Centers of Disease control and Prevention (CDC). Guidelines for maintaining and managing the vaccine cold chain. MMWR Morb Mortal Wkly Rep 2003;52:1023-5.
22. Porras M, Solans C, Gonzalez C, Gutierrez JM. Properties of water-in-oil (W/O) nano-emulsions prepared by a low-energy emulsifica-tion method. Colloids Surf A: Physicochem Eng Asp 2008;324:181-8.
23. Bali V, Ali M, Ali J. Study of surfactant combinations and development of a novel nanoemulsion for minimizing variations in bioavailability of ezetimibe. Colloids Surf B: Biointerfaces 2010;76:410-20.
24. Azeem A, Rizwan M, Ahmad FJ, et al. Nanoemulsion components screening and selection: a technical note. AAPS Pharm Sci Tech 2009;10:69-76.
25. Kumar M, Pathak K, Misra A. Formulation and characterization of nanoemulsion-based drug delivery system of risperidone. Drug Dev Ind Pharm 2009;35:387-95.
26. D'Hondt E, Hehme N, Hanon EJ, Stephenne J. Influenza vaccine. United States of America patent US 2007/0141078 A1, 21 Jun 2007.
27. Morel S, Didierlaurent A, Bourguignon P, et al. Adjuvant system AS03 containing a-tocopherol modulates innate immune response and leads to improved adaptive immunity. Vaccine 2011;29:2461-73.
28. Ferguson M, Risi G, Davis M, et al. Safety and long-term humoral immune response in adults after vaccination with an H1N1 2009 pandemic influenza vaccine with or without AS03 adjuvant. J Infect Dis 2012;205:733-44.
29. Alonso PL, Sacarlal J, Aponte JJ, et al. Efficacy of the RTS, S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet 2004;364:1411-20.
30. Baldwin SL, Fox CB, Pallansch MA, et al. Increased potency of an inactivated trivalent polio vaccine with oil-in-water emulsions. Vaccine 2011;29:644-9.
31. Bertholet S, Goto Y, Carter L, et al. Optimized subunit vaccine protects against experimental leishmaniasis. Vaccine 2009;27:7036-45.
32. Baldwin SL, Shaverdian N, Goto Y, et al. Enhanced humoral and type 1 cellular immune responses with Fluzone adjuvanted with a synthetic TLR4 agonist formulated in an emulsion. Vaccine 2009;27:5956-63.
33. Baldwin SL, Bertholet S, Kahn M, et al. Intradermal immunization improves protective efficacy of a novel TB vaccine candidate. Vaccine 2009;27:3063-71.
34. Fox CB, Anderson RC, Dutill TS, et al. Monitoring the effects of component structure and source on formulation stability and adjuvant activity of oil-in-water emulsions. Colloids Surf B: Biointerfaces 2008;65:98-105.
35. Otto A, Du Plessis J, Wiechers JW. Formulation effects of topical emulsions on transdermal and dermal delivery. Int J Cosmet Sci 2009;31:1-19.
36. Ott G, Radhakrishnan R, Fang JH, Hora M. The adjuvant MF59: a 10-year perspective. In: O'Hagan DT, ed. Vaccine adjuvants: preparation methods and research protocols. Totowa (NJ): Humana Press Inc.; 2000:211-28.
37. Podda A. The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. Vaccine 2001;19:2673-80.
38. Ott G, Barchfeld GL, Van Nest G. Enhancement of humoral response against human influenza vaccine with the simple submicron oil/water emulsion adjuvant MF59. Vaccine 1995;13:1557-62.
39. Rangsansarid J, Fukada K. Factors affecting the stability of O/W emulsion in BSA solution: stabilization by electrically neutral protein at high ionic strength. J Colloid Interface Sci 2007;316:779-86.
40. Gillet A, Compere P, Lecomte F, et al. Liposome surface charge influence on skin penetration behaviour. Int J Pharm 2011;411:223-31.